Alder BioPharma CEO and founder steps down as its lead migraine drug approaches FDA approval

News Brief: Randall Schatzman, the CEO and president of Bothell, Wash., company Alder BioPharmaceuticals, is stepping down from his role as CEO and president and will also vacate his seat on the company’s board of directors, the company announced Wednesday. He will remain a consultant while the company seeks a new CEO. Paul Cleveland, a member of the company’s board of directors, will serve as interim CEO.  Alder is in the final stages of clinical trials for its antibody-based migraine treatment, eptinezumab.